Aryl hydrocarbon receptor (AHR) agonists and uses thereof

A method for reducing the risk of an angiogenesis implicated disorder or an inflammatory disorder in a patient comprising administering to the patient a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is
• wherein R12 is halogen, —CN, —NO2, RW, —C(O)—RW, —C(═NRW)—RW, —N(RW)—C(O)—RW, —N(RW)—C(═NRW)—RW, —OC(O)—RW, —OC(═NRW)—RW, —S(O)2—RW, —N(RW)—S(O)2—RW, —OS(O)2—RW, —S(O)—RW, —N(RW)—S(O)—RW, or —OS(O)—RW;
• Ring B is
• wherein each of R6, R7, R8, and R10 is independently halogen, —CN, —NO2, RW, —C(O)—RW, —C(═NRW)—RW, —N(RW)—C(O)—RW, —N(RW)—C(═NRW)—RW, —OC(O)—RW, —OC(═NRW)—RW, —S(O)2—RW, —N(RW)—S(O)2—RW, —OS(O)2—RW, —S(O)—RW, —N(RW)—S(O)—RW, or —OS(O)—RW;
• R9 is —N(R)2,
• each R′ is independently halogen, —CN, —NO2, R, —OR, —SR, —N(R)2, —C(O)OR, or —C(O)N(R)2;
• and
• m is 0, 1, 2, 3, 4, or 5;
• Ring C is
• wherein each of R1, R3, R4, and R5 is independently halogen, —CN, —NO2, RW, —C(O)—RW, —C(═NRW)—RW, —N(RW)—C(O)—RW, —N(RW)—C(═NRW)—RW, —OC(O)—RW, —OC(═NRW)—RW, —N(RW)—S(O)2—RW, —OS(O)2—RW, —S(O)2−RW, —S(O)—RW, —N(RW)—S(O)—RW, or —OS(O)—RW;
• and R2 is -C1-6 aliphatic substituted 1-6 times by halogen;
• provided that when R2 is CF3, then R9 is not —N(CH3)2 or —N(CH2CH3)2;
• R11 is —R, —C(O)—RW, —C(═NRW)—RW, —S(O)2—RW, or —S(O)—RW;
• RW is —R, —N(R)2, —NR—OR, —N(R)—N(R)2, —N(OR)—N(R)2, —N(R)—N(OR)R, —OR, —O—N(R)2, or —SR;
• and
• R is hydrogen, or optionally substituted C1-6 aliphatic,
• provided that the compound is not